Analysts Mixed As Australia’s CSL Moves To Settle U.S. Price Fixing Case
This article was originally published in PharmAsia News
Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.
You may also be interested in...
Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.
CSL CEO Brian McNamee On Being Australia's Only Homegrown MNC: An Interview With PharmAsia News (Part 2 of 2)
[Editor's note: This is part two of a two-part interview. Part one appeared in PharmAsia News, June 1, 2009.]
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.